Molecular tumor board in patients with metastatic breast cancer.

IF 3 3区医学 Q2 ONCOLOGY

Breast Cancer Research and Treatment Pub Date : 2024-10-30 DOI:10.1007/s10549-024-07535-z

Luca Boscolo Bielo, Elena Guerini Rocco, Edoardo Crimini, Matteo Repetto, Mariano Lombardi, Cristina Zanzottera, Gaetano Aurilio, Massimo Barberis, Carmen Belli, Yinxiu Zhan, Elena Battaiotto, Jalissa Katrini, Renato Marsicano, Paola Zagami, Beatrice Taurelli Salimbeni, Angela Esposito, Dario Trapani, Carmen Criscitiello, Nicola Fusco, Antonio Marra, Giuseppe Curigliano

{"title":"Molecular tumor board in patients with metastatic breast cancer.","authors":"Luca Boscolo Bielo, Elena Guerini Rocco, Edoardo Crimini, Matteo Repetto, Mariano Lombardi, Cristina Zanzottera, Gaetano Aurilio, Massimo Barberis, Carmen Belli, Yinxiu Zhan, Elena Battaiotto, Jalissa Katrini, Renato Marsicano, Paola Zagami, Beatrice Taurelli Salimbeni, Angela Esposito, Dario Trapani, Carmen Criscitiello, Nicola Fusco, Antonio Marra, Giuseppe Curigliano","doi":"10.1007/s10549-024-07535-z","DOIUrl":null,"url":null,"abstract":"Purpose: Comprehensive genomic profiling is becoming increasingly important in the management of patients with metastatic breast cancer (mBC). Real-world clinical outcomes from applying molecular tumor boards (MTBs) recommendations in this context remain limited. Accordingly, we conducted a retrospective, single-institution analysis to evaluate the clinical impact of discussing patients affected by mBC at the MTB.Methods: Clinicogenomic data of patients affected by mBCs referred to the European Institute of Oncology MTB between August 2019 and December 2023 were reviewed. Genomic alterations were classified by ESCAT framework. Clinical outcomes of patients showing actionable alterations and receiving molecular-matched therapy (MMT) were compared to those receiving standard therapy (ST).Results: Ninety-six patients were included. Following MTB discussion, genetic counseling was recommended in 27% (n = 26) of patients, while additional molecular analyses were requested in 25% (n = 24) cases. Fifty-six patients (58%) displayed at least one actionable alteration. For patients with available follow-up (n = 50), 32 (64%) received MMTs and 18 (36%) ST. No differences in real-world progression-free survival (rwPFS) (4.07 months [95% CI 2.14-8.28] vs. 3.12 months [95% CI 1.51-NE], P = 0.8) and 12-month overall survival (OS) (58% [95%CI 43-78] vs. 57% [95%CI 34-97), P = 0.9) were observed between the MMT- and ST-group. Level I ESCAT alterations yielded longer rwPFS (5.82 months [95% CI 3.12-8.41]) compared to ESCAT II (2.14 months [95%CI 1.61-NE]) and ESCAT III (2.10 months [95% CI 2.04-NE]; P = 0.03). Twenty-four percent of patients showed a PFS2/PFS1 ratio > 1.3 from MMT.Conclusion: Molecular tumor boards can provide additional treatment options for patients affected by mBC. Besides treatment recommendations, MTBs also have the utility to assess the validity of discussed genomic reports and to identify alterations worthy of genetic counseling.","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07535-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Comprehensive genomic profiling is becoming increasingly important in the management of patients with metastatic breast cancer (mBC). Real-world clinical outcomes from applying molecular tumor boards (MTBs) recommendations in this context remain limited. Accordingly, we conducted a retrospective, single-institution analysis to evaluate the clinical impact of discussing patients affected by mBC at the MTB.

Methods: Clinicogenomic data of patients affected by mBCs referred to the European Institute of Oncology MTB between August 2019 and December 2023 were reviewed. Genomic alterations were classified by ESCAT framework. Clinical outcomes of patients showing actionable alterations and receiving molecular-matched therapy (MMT) were compared to those receiving standard therapy (ST).

Results: Ninety-six patients were included. Following MTB discussion, genetic counseling was recommended in 27% (n = 26) of patients, while additional molecular analyses were requested in 25% (n = 24) cases. Fifty-six patients (58%) displayed at least one actionable alteration. For patients with available follow-up (n = 50), 32 (64%) received MMTs and 18 (36%) ST. No differences in real-world progression-free survival (rwPFS) (4.07 months [95% CI 2.14-8.28] vs. 3.12 months [95% CI 1.51-NE], P = 0.8) and 12-month overall survival (OS) (58% [95%CI 43-78] vs. 57% [95%CI 34-97), P = 0.9) were observed between the MMT- and ST-group. Level I ESCAT alterations yielded longer rwPFS (5.82 months [95% CI 3.12-8.41]) compared to ESCAT II (2.14 months [95%CI 1.61-NE]) and ESCAT III (2.10 months [95% CI 2.04-NE]; P = 0.03). Twenty-four percent of patients showed a PFS2/PFS1 ratio > 1.3 from MMT.

Conclusion: Molecular tumor boards can provide additional treatment options for patients affected by mBC. Besides treatment recommendations, MTBs also have the utility to assess the validity of discussed genomic reports and to identify alterations worthy of genetic counseling.

查看原文本刊更多论文

转移性乳腺癌患者的肿瘤分子板。

目的：综合基因组分析在转移性乳腺癌（mBC）患者的治疗中变得越来越重要。在这种情况下应用分子肿瘤委员会（MTB）建议所产生的实际临床效果仍然有限。因此，我们进行了一项单一机构的回顾性分析，以评估在MTB上讨论mBC患者的临床影响：我们回顾了2019年8月至2023年12月期间转诊至欧洲肿瘤研究所MTB的mBC患者的临床基因组数据。根据ESCAT框架对基因组改变进行分类。将显示可操作改变并接受分子匹配疗法（MMT）的患者的临床结果与接受标准疗法（ST）的患者的临床结果进行比较：结果：共纳入 96 例患者。经过MTB讨论后，27%的患者（n = 26）被建议进行遗传咨询，25%的患者（n = 24）被要求进行额外的分子分析。56 例患者（58%）至少出现了一种可操作的改变。在接受随访的患者中（50 例），32 例（64%）接受了 MMTs 治疗，18 例（36%）接受了 ST 治疗。MMT组和ST组患者的实际无进展生存期（rwPFS）（4.07个月 [95% CI 2.14-8.28] vs. 3.12个月 [95% CI 1.51-NE]，P = 0.8）和12个月总生存期（OS）（58% [95%CI 43-78] vs. 57% [95%CI 34-97)，P = 0.9）未见差异。与ESCAT II（2.14个月[95%CI 1.61-NE]）和ESCAT III（2.10个月[95%CI 2.04-NE]；P = 0.03）相比，ESCAT I级改变可获得更长的rwPFS（5.82个月[95%CI 3.12-8.41]）。24%的患者的MMT PFS2/PFS1比值大于1.3：结论：分子肿瘤委员会可为乳腺癌患者提供更多治疗选择。除了治疗建议外，MTB 还可以评估讨论过的基因组报告的有效性，并确定值得进行遗传咨询的改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Research and Treatment 医学-肿瘤学

CiteScore

6.80

自引率

2.60%

发文量

342

审稿时长

1 months

期刊介绍： Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.